阳光诺和：与乐旷惠霖合作开发STC007项目 合同金额2亿元

Group 1 - The core point of the article is that Yangguang Nuohuo has signed a cooperation contract with Shanghai Lekuang Huilin Pharmaceutical Technology Co., Ltd. to develop the STC007 project, with a total contract amount of 200 million yuan [1] - The STC007 project, which targets pain relief indications, has received approval for clinical trials and is currently in Phase III clinical trials [1] - The signing of the agreement is expected to have a positive impact on the company's future performance and enhance its profitability [1] Group 2 - The sales performance of the new drug after its launch will be influenced by market conditions and industry development, indicating uncertainty [1]